BIMINI Biotech
BIMINI Biotech is an innovative spin-off company of the Institute of Oncology Research (IOR), which has been launched at the end of 2019. The company develops innovative first-in-class therapeutics for oncology, with a particular emphasis on lymphomas and leukemia. BIMINI Biotech's strategy is founded on targeting the Wiskott-Aldrich-Syndrome Protein, which has been shown to play a significant role in the malignancy of lymphoma tumors; by activating this protein, it is possible to perturb lymphomas resulting in cancer cells' death. The patent protected technology is founded on pioneering research conducted by the group of Francesco Bertoni, professor at the Università della Svizzera italiana (USI) and IOR Deputy-Director.
